Zobrazeno 81 - 90
of 283
pro vyhledávání: '"Michael R McClung"'
Autor:
Michael R. McClung, Claude-Laurent Benhamou, Peter Mesenbrink, Chris Recknor, Christina Bucci-Rechtweg, Paul Miller
Publikováno v:
Obstetrics & Gynecology. 114:999-1007
To evaluate the efficacy of zoledronic acid in the prevention of bone loss in postmenopausal women with low bone mass.In this 2-year, randomized, multicenter, double-blind, placebo-controlled study, postmenopausal women with low bone mass were select
Autor:
Henry G. Bone, Arthur C. Santora, Robert R. Recker, Michael R. McClung, John A. Eisman, Carolyn M. Hustad, Christian Roux, Carolyn DaSilva, B Avery Ince, N. Verbruggen
Publikováno v:
Journal of Bone and Mineral Research, 25(5), 937-947. Wiley
Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen. Odanacatib selectively and reversibly inhibited cathepsin K and rapidly decreased bone resorption in preclinical and phase I studies. A 1-year dose-finding trial wit
Publikováno v:
Contraception. 77:67-76
While depot medroxyprogesterone acetate (DMPA) is a highly effective contraceptive used by millions of women, its use is associated with bone mineral density (BMD) loss, raising concerns about long-term risk of osteoporosis and/or fractures.We conduc
Autor:
Christian Roux, Ellen Matzkin, Rachelle Eusebio, Claude-Laurent Benhamou, Michael R. McClung, Z. Man, John F. Beary, Artur J. Racewicz, Pierre D. Delmas, David Ernest Burgio, Jose R. Zanchetta, Steven Boonen
Publikováno v:
Bone. 42:36-42
Introduction: Risedronate has been shown to be effective in the treatment of postmenopausal osteoporosis when given orally in daily or weekly doses or on 2 consecutive days per month. This randomized, double-blind, multi-center study was designed to
Publikováno v:
Osteoporosis International
Summary This posthoc analysis of four trials studied the efficacy of risedronate to reduce fragility fractures in postmenopausal women with osteopenia (i.e., T-scores between −1 and −2.5). Risedronate reduced the fracture risk by 73% ( = 0.023) i
Autor:
S. Adami, M. L. Brandi, L. Xie, Manuel Muñoz-Torres, J. San Martin, Michael R. McClung, Gail P Dalsky, Jeremy P Brown, A. Sipos, Dieter Felsenberg, Michael J. Econs
Publikováno v:
Osteoporosis International. 19:87-94
Loss of bone mineral density occurs after discontinuation of teriparatide, if no subsequent treatment is given. Sequential raloxifene prevented rapid bone loss at lumbar spine and further increased bone mineral density (BMD) at femoral neck, whether
Autor:
S. Siddhanti, Michael A. Bolognese, Lorraine A. Fitzpatrick, Michael R. McClung, Yu Liu, Paul D. Miller, E. Michael Lewiecki, Stanley Cohen, Andrea Wang
Publikováno v:
Journal of Bone and Mineral Research. 22:1832-1841
Denosumab is a monoclonal antibody to RANKL. In this randomized, placebo-controlled study of 412 postmenopausal women with low BMD, subcutaneous denosumab given every 3 or 6 mo was well tolerated, increased BMD, and decreased bone resorption markers
Autor:
Michael R McClung
Publikováno v:
BoneKEy-Osteovision. 4:78-82
Bisphosphonate therapy is now the mainstay of treatment for patients with primary and secondary forms of osteoporosis. This class of drugs has earned this role because of multiple studies documenting the reduction in the incidence of vertebral and ot
Autor:
Toshitaka Nakamura, W. J. Shih, Antonio Lombardi, N. Verbruggen, David W. Dempster, A. T. Leung, Arthur C. Santora, John A. Eisman, A Rybak-Feiglin, Susan L. Greenspan, Henry G. Bone, Michael R. McClung, S. Papapoulos
Publikováno v:
Osteoporosis International, 26(2), 699-712
Osteoporosis International
Osteoporosis International
Summary Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and increases bone mineral density, with only a transient decrease in b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f6546cedd385001744026d081e7faa
https://hdl.handle.net/1887/107872
https://hdl.handle.net/1887/107872
Autor:
S. Siddhanti, Henry G. Bone, E. Michael Lewiecki, Roland Chapurlat, Edward Czerwiński, Bente L. Langdahl, Alan Kivitz, Ugis Gruntmanis, Bo Abrahamsen, P.R. Ho, Michael R. McClung, Rachel B. Wagman, Y.-C. Yang, Faisal M. Mirza, Michael A. Bolognese, Östen Ljunggren, Christence S. Teglbjaerg, Jean-Yves Reginster, David L. Kendler, Eric S. Orwoll, Paul D. Miller
Publikováno v:
Langdahl, B L, Teglbjaerg, C S, Ho, P-R, Chapurlat, R, Czerwinski, E, Kendler, D L, Reginster, J-Y, Kivitz, A, Lewiecki, E M, Miller, P D, Bolognese, M A, McClung, M R, Bone, H G, Ljunggren, Ö, Abrahamsen, B, Gruntmanis, U, Yang, Y-C, Wagman, R B, Mirza, F, Siddhanti, S & Orwoll, E 2015, ' A 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density : Results From the ADAMO Trial ', Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 4, pp. 1335–1342 . https://doi.org/10.1210/jc.2014-4079
Langdahl, B L, Teglbjaerg, C S, Ho, P-R, Chapurlat, R, Czerwinski, E, Kendler, D L, Reginster, J-Y, Kivitz, A, Lewiecki, E M, Miller, P D, Bolognese, M A, McClung, M R, Bone, H G, Ljunggren, Ö, Abrahamsen, B, Gruntmanis, U, Yang, Y-C, Wagman, R B, Mirza, F, Siddhanti, S & Orwoll, E 2015, ' A 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density : Results From the ADAMO Trial ', Journal of Clinical Endocrinology and Metabolism, pp. jc20144079 . https://doi.org/10.1210/jc.2014-4079
Langdahl, B L, Teglbjaerg, C S, Ho, P-R, Chapurlat, R, Czerwinski, E, Kendler, D L, Reginster, J-Y, Kivitz, A, Lewiecki, E M, Miller, P D, Bolognese, M A, McClung, M R, Bone, H G, Ljunggren, Ö, Abrahamsen, B, Gruntmanis, U, Yang, Y-C, Wagman, R B, Mirza, F, Siddhanti, S & Orwoll, E 2015, ' A 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density : Results From the ADAMO Trial ', Journal of Clinical Endocrinology and Metabolism, pp. jc20144079 . https://doi.org/10.1210/jc.2014-4079
Context: One in 4 men in the United States aged >50 years will have an osteoporosis-related fracture. Fewer data are available on osteoporosis treatment in men than in women. Objective: The purpose of this study was to evaluate denosumab therapy in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20da2c31e9f294348537f6c1eccbe1f2
https://acuresearchbank.acu.edu.au/item/8833y/a-24-month-study-evaluating-the-efficacy-and-safety-of-denosumab-for-the-treatment-of-men-with-low-bone-mineral-density-results-from-the-adamo-trial
https://acuresearchbank.acu.edu.au/item/8833y/a-24-month-study-evaluating-the-efficacy-and-safety-of-denosumab-for-the-treatment-of-men-with-low-bone-mineral-density-results-from-the-adamo-trial